Article citationsMore>>
Robidoux, A., Buzdar, A.U., Quinaux, E., Jacobs, S., Rastogi, P., Fourchotte, V., Younan, R.J., Pajon, E.R., Shalaby, I.A., Desai, A.M., Fehrenbacher, L., Geyer, C.E., Mamounas, E.P. and Wolmark, N.A. (2010) Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-fluorouracil/epirubicin Cyclophosphamidein Locally Advanced Breast Cancer. Clinical Breast Cancer, 10, 81-86.
https://doi.org/10.3816/CBC.2010.n.011
has been cited by the following article:
-
TITLE:
Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient
AUTHORS:
Maria Rosaria Valerio, Chiara Ancona, Antonella Marchese, Vittorio Gebbia
KEYWORDS:
Nab-Paclitaxel, Trastuzumab, HER-2, Metastasis, Breast Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.11,
November
16,
2017
ABSTRACT: Background: Agent targeting HER-2 pathway
plus chemotherapy has represented a major
progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily
pretreated patients is still largely unclear. In the last decade, nab-paclitaxel has shown significant activity
and good toxicity profile in metastatic breast cancer. Case Presentation: We report the case of a 76-year-old Caucasian woman
with metastatic HER-2 positive ductal infiltrating breast carcinoma treated
with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line
therapy. She had previously received first-line paclitaxel and trastuzumab,
second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral
capecitabine and lapatinib. Clinical and radiological staging showed
progression at bone, skin and soft-tissue. The patient received weekly
nab-paclitaxel plus trastuzumab. Massive objective response was clinically and
PET documented which lasted 8 months. Tolerance to treatment was fairly good as
well as cardiac safety. Conclusion: To the best of our knowledge, this
is the first reported case of efficacy of nab-paclitaxel in combination with
trastuzumab as fifth-line of treatment in a patient with metastatic HER-2
positive breast cancer.
Related Articles:
-
Manal M. El-Mahdy, Riham A. Ibrahim, Radwa M. Hamed, Mohamaad S. Elkady, Walid A. Bayoumy, Zeinab M. Elsayed, Mai M. Ezz-El-Din
-
Zheng Nie
-
Vijayashree Murthy, K. S. Gopinath, Anand Krishna
-
Yun Xi, Min Zhang, Rui Guo, Miao Zhang, Jiajia Hu, Biao Li
-
Basem Battah, Jumana Saleh, Marroan Bachour, Maher Salamoon